The company announced that the first subjects have been dosed in a Phase-1 clinical trial of SUVN-I6107 in the USA.
The company's board approved raising funds through issuance and allotment of equity shares having face value of Re 1 each up to an aggregate amount of Rs 400 crore on rights basis, Suven Life Sciences said in a regulatory filing.
The share touched a 52 week high of Rs 124.40 and a 52 week low of Rs 62.00 on 8 October 2021 and 20 June 2022 respectively